What we do Emcure Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in developing, manufacturing, and marketing a wide range of pharmaceutical products globally across major therapeutic areas including gynecology, cardiovascular, oncology, and biologics. |
Founded in 1,981 |
Market share Emcure ranks #2 in gynecology in India, is among the top generic pharmaceutical players in Canada, and holds leadership in multiple therapeutic areas globally. |
Problem solved The company addresses healthcare needs by offering complex APIs, biologics, biosimilars, and novel drug delivery systems for acute and chronic diseases. |
Top clients or who we serve Emcure serves global markets including India, Europe, North America, Asia-Pacific; its clients include hospitals, healthcare providers, and pharmaceutical distributors (B2B and B2C). |
Key management Mrs. Namita Thapar (Whole-time Director) with over 20 years pharma leadership; management team with extensive industry experience. |
Our journey and innovations Founded in 1981, expanded through amalgamation and acquisitions; developed chiral molecules, biosimilars, novel drug delivery systems; launched biologics and complex injectables; listed publicly in 2024. |
Where we operate Operations span India, Europe, North America, Chile, Philippines, Malta with exports to 900+ countries worldwide. |
Top products or what we offer Portfolio includes biosimilars (Tenectase, Pegylated-asparaginase), complex injectables, formulations in gynecology, cardiovascular, oncology, dermatology, and consumer health under 'Arth'. |
Top brands Elaxim, Tenectase, Hamsyl, BiCNUr (oncology), Arth (consumer health); market leaders in gynecology and injectables segments. |
Raw materials needed Active pharmaceutical ingredients (APIs), complex intermediates, biologic raw materials, specialty chemicals for drug formulations. |
Raw materials supplier Global and domestic ingredient suppliers; partnerships and in-house bulk manufacturing for selected APIs. |
Recurring vs cyclical contribution Majority revenue from recurring pharmaceutical product sales with steady demand across markets. |
Our industry position Strong competitive positioning in India and international markets, with differentiated biologics and complex injectable portfolios. |
Financial highlights FY25 consolidated revenue ₹7,896 crore, PAT ₹681 crore; revenue grew 18% year-on-year with margin expansion and strong operating leverage. |
Geographical revenue split India 46%, Europe 19%, North America 16%, Other regions 19% of total revenue in FY25. |
Order book Robust product pipeline with over 50 products in development including biologics, complex injectables, and biosimilars; strong ARV order book. |
Whats driving growth Growth fueled by faster-than-industry expansion, new launches, innovation in biologics and drug delivery, strategic in-licensing, and expanding global footprint. |
Our future plans Focus on pipeline commercialization, dermatology expansion via Emcutix, consumer health growth, and investment in R&D for novel therapies. |
Our green promise Investment in solar energy through associate Sunsure Solarpark; commitment to sustainable manufacturing and CSR initiatives. |
Our people and values 6,700+ employees fostering a culture of innovation, ethics, inclusion, and continuous development. |
Key challenges ahead Regulatory compliance across geographies, pricing pressures, competition in generics, and evolving patent landscapes. |
Interesting facts Holds global patents, launched India’s first biosimilar Tenecteplase for myocardial infarction, expanding into dermatology and consumer wellness sectors. |
Risks and strategy Mitigates risks via diversified portfolio, robust compliance, innovative R&D, and strategic acquisitions to sustain growth and market leadership. |
